Khalid, Sara
Prieto-Alhambra, Daniel
Funding for this research was provided by:
University of Oxford
Article History
First Online: 27 July 2019
Compliance with Ethical Standards
:
: Sara Khalid declares no potential conflicts of interest. Daniel Prieto-Alhambra reports research grants and advisory and speaker fees paid to his department from Amgen, research grants and advisory and consultancy fees paid to his department from UCB Biopharma SRL and research grants from Servier, Astellas, Novartis and GSK, outside the submitted work.
: This article does not contain any studies with human or animal subjects performed by any of the authors.